支持多系统性缩患者的支持需求
Julia Ly Cheong1, Zhao Hk Goh1, Anette Schrag2
1Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Parkinsonism & related disorders
|February 13, 2024
概括
多系统缩 (MSA) 显著影响患者的生活质量,主要关注的是运动和自主性问题. 这项研究强调,需要为患有MSA的人提供更好的情感和社会支持.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 患者支持服务服务.
背景情况:
- 多重系统缩 (MSA) 是一种渐进的神经退行性疾病.
- MSA表现为帕金森症,自主功能障碍,步态障碍和情绪障碍.
- 这种疾病显著降低了患者的生活质量.
研究的目的:
- 评估英国MSA (PwMSA) 患者的需求.
- 评估PwMSA目前可用的支持系统.
- 为了识别MSA患者的护理缺口.
主要方法:
- 一项调查分发给英国MSA信托的成员.
- 包括患有MSA (PwMSA) 的人和前照顾者.
- 探讨了MSA的身体,情感,个人和财务影响以及所获得的支持.
主要成果:
- 在PwMSA中,移动困难是普遍存在的;90%的护理人员发现他们难以管理.
- 自主 (85%) 和呼吸/吞 (81%) 问题也是重大挑战.
- 普华永道报告称,高水平的疲劳 (96%),社会孤立 (82%),以及未得到满足的情感 (41%) 和财务 (48%) 需求.
结论:
- 对于患者来说,MSA在多个生活领域施加了相当大的负担.
- 虽然神经学和身体设备支持是好的,但情感和社会支持需要增强.
- 改善综合护理对于在MSA获得更好的结果至关重要.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
Documentation in Long-Term and Home Healthcare Setting
892
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
892
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268


